A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia (SHINE)

Study Title
A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients With Schizophrenia
Teva Identifier
TV46000-CNS-30078
ClinicalTrials.gov Identifier
NCT03893825
Study Status
Completed
Trial Condition(s)
Schizophrenia
Interventions
Drug: TV-46000 | Drug: Placebo
EudraCT Number
2019-000063-24
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
psychiatry-icon

Key Participation Requirements

Gender
Female, Male
Age group
Child, Adult, Older Adult
Age Range
13 Years to 65 Years
Trial Duration
April 17, 2019 - December 02, 2021
Phase
Phase 3

Study Type

Interventional